Highlights from the EULAR International Congress 2021 – Slide kit

Nuove analisi su SSc-ILD e PF-ILD presentate al Congresso Internazionale EULAR, 2-5 Giugno 2021

Nel seguente slide kit sono riportate le evidenze scientifiche più rilevanti su SSc-ILD e PF-ILD emerse dal Congresso Internazionale EULAR 2021:

• Decline in FVC in patients with SSc-ILD with and without dyspnoea: data from the SENSCIS trial (Volkmann ER et al.)
• Risk of malnutrition in patients with SSc-ILD: further analyses of the SENSCIS trial. (Volkmann ER et al.)
• Decline in FVC in subjects with SSc-ILD in the SENSCIS trial versus hypothetical reference subjects without lung disease. (Maher TM et al.)
• Efficacy of nintedanib in patients with SSc-ILD and internal organ involvement: data from the SENSCIS trial. (Allanore Y et al.)
• Post-trial survey of participants of a Phase 3 clinical trial in SSc-ILD (Galetti I et al)
• Patient preferences for the treatment of SSc-ILD: a discrete choice experiment (Bruni C et al)
• Modelling short-term FVC changes from SENSCIS to long-term FVC course in SSc-ILD demonstrates clinically meaningful reduction of FVC decline and survival benefits (Hoffmann-Vold AM et al)
• Effects of nintedanib in patients with RA-ILD in the INBUILD trial. (Kelly C et al.)